Cargando…
Repurposing drugs to treat cardiovascular disease in the era of precision medicine
Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The concept is appealing because of potentially lower development costs and shorter timelines than are needed to produce a new drug. To date, drug repurposing fo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125554/ https://www.ncbi.nlm.nih.gov/pubmed/35606425 http://dx.doi.org/10.1038/s41569-022-00717-6 |
_version_ | 1784711961688145920 |
---|---|
author | Abdelsayed, Mena Kort, Eric J. Jovinge, Stefan Mercola, Mark |
author_facet | Abdelsayed, Mena Kort, Eric J. Jovinge, Stefan Mercola, Mark |
author_sort | Abdelsayed, Mena |
collection | PubMed |
description | Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The concept is appealing because of potentially lower development costs and shorter timelines than are needed to produce a new drug. To date, drug repurposing for cardiovascular indications has been opportunistic and driven by knowledge of disease mechanisms or serendipitous observation rather than by systematic endeavours to match an existing drug to a new indication. Innovations in two areas of personalized medicine — computational approaches to associate drug effects with disease signatures and predictive model systems to screen drugs for disease-modifying activities — support efforts that together create an efficient pipeline to systematically repurpose drugs to treat cardiovascular disease. Furthermore, new experimental strategies that guide the medicinal chemistry re-engineering of drugs could improve repurposing efforts by tailoring a medicine to its new indication. In this Review, we summarize the historical approach to repurposing and discuss the technological advances that have created a new landscape of opportunities. |
format | Online Article Text |
id | pubmed-9125554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-91255542022-05-23 Repurposing drugs to treat cardiovascular disease in the era of precision medicine Abdelsayed, Mena Kort, Eric J. Jovinge, Stefan Mercola, Mark Nat Rev Cardiol Review Article Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The concept is appealing because of potentially lower development costs and shorter timelines than are needed to produce a new drug. To date, drug repurposing for cardiovascular indications has been opportunistic and driven by knowledge of disease mechanisms or serendipitous observation rather than by systematic endeavours to match an existing drug to a new indication. Innovations in two areas of personalized medicine — computational approaches to associate drug effects with disease signatures and predictive model systems to screen drugs for disease-modifying activities — support efforts that together create an efficient pipeline to systematically repurpose drugs to treat cardiovascular disease. Furthermore, new experimental strategies that guide the medicinal chemistry re-engineering of drugs could improve repurposing efforts by tailoring a medicine to its new indication. In this Review, we summarize the historical approach to repurposing and discuss the technological advances that have created a new landscape of opportunities. Nature Publishing Group UK 2022-05-23 2022 /pmc/articles/PMC9125554/ /pubmed/35606425 http://dx.doi.org/10.1038/s41569-022-00717-6 Text en © Springer Nature Limited 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Abdelsayed, Mena Kort, Eric J. Jovinge, Stefan Mercola, Mark Repurposing drugs to treat cardiovascular disease in the era of precision medicine |
title | Repurposing drugs to treat cardiovascular disease in the era of precision medicine |
title_full | Repurposing drugs to treat cardiovascular disease in the era of precision medicine |
title_fullStr | Repurposing drugs to treat cardiovascular disease in the era of precision medicine |
title_full_unstemmed | Repurposing drugs to treat cardiovascular disease in the era of precision medicine |
title_short | Repurposing drugs to treat cardiovascular disease in the era of precision medicine |
title_sort | repurposing drugs to treat cardiovascular disease in the era of precision medicine |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125554/ https://www.ncbi.nlm.nih.gov/pubmed/35606425 http://dx.doi.org/10.1038/s41569-022-00717-6 |
work_keys_str_mv | AT abdelsayedmena repurposingdrugstotreatcardiovasculardiseaseintheeraofprecisionmedicine AT kortericj repurposingdrugstotreatcardiovasculardiseaseintheeraofprecisionmedicine AT jovingestefan repurposingdrugstotreatcardiovasculardiseaseintheeraofprecisionmedicine AT mercolamark repurposingdrugstotreatcardiovasculardiseaseintheeraofprecisionmedicine |